Wednesday, July 1, 2009

AMAG wins FDA approval for kidney drug

By Julie M. Donnelly

Video Gallery

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds

MHT's Marc Songini: RI plans launch of cord blood center

Related News

3SBio pays AMAG Pharma $1M to sell ferumoxytol in China [May 27, 2008]

Cubist exec Perez joins AMAG Pharmaceuticals board [January 27, 2009]

AMAG Pharma’s CKD diagnostics on FDA Fast Track [August 21, 2008]

Real Deal: MIT buys biotech buildings from family trust for $90M [July 3, 2008]

Marshall Edwards faces stock delisting [March 19, 2010]

AMAG Pharmaceuticals Inc. has won U.S. Food and Drug Administration approval for its drug, called Feraheme, to treat chronic kidney disease. The Lexington-based company’s drug is an injection designed to be used as an iron replacement therapy to fight anemia in patients with kidney disease. The drug can be used by patients who are on or off dialysis.

The drug is expected to be available commercially later this month and will be distributed primarily through wholesalers and specialty distributors.

AMAG had $195 million of cash on hand as of March 31. The company reported a net loss of 27 million in the first quarter of 2009.

AMAG’s (Nasdaq:AMAG) stock ticked up almost 3 percent in midday trading on Wednesday, to $56.69 up from $54.69 at the previous close.